TFDP3 and T-cell acute lymphoblastic leukemia: Intriguingly, TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia, and downregulation of TFDP3 by RNA interference sensitizes cancer cells to combinational chemotherapy.